Nestlé invests another $200 million in Aimmune’s peanut allergy drug

February 6, 2020, 12:06 AM UTC

This is the web version of Brainstorm Health Daily, Fortune’s daily newsletter on the top health care news. To get it delivered daily to your in-box, sign up here.

Good afternoon, readers.

Last week, the Food and Drug Administration (FDA) approved the first-ever treatment for peanut allergies in young patients, Aimmune Therapeutics’s Palforzia. And the victory is already paying dividends for the biotech firm.

On Wednesday, food giant Nestlé’s Health Science arm announced an additional $200 million investment in Aimmune (on top of a $273 million existing stake, bring the total to $473 million).

It’s a convertible stock deal by Nestlé, which clearly has an interest in a company that’s on the bleeding edge of drug development for one of the most prevalent food allergies in the world—one that’s innately important for a global firm that manufactures foods which may contain peanuts. Nestlé’ food companies include ice cream brands, food service providers, candy makers, and much more.

“We are impressed with the progress Aimmune has made as it prepares to launch Palforzia, the first drug approved by the FDA for any form of food allergy,” said Nestlé Health Science CEO Greg Behar in a statement.

Palforzia was approved last Friday but, when it comes to its sales potential, the drug has faced some controversy among the investor class.

For instance, the treatment—which uses a formulation of peanut protein in order to get children who have deadly allergies used to the substance—requires significant oversight and eventual “up-dosing.” That’s a complicated process for a potentially deadly condition, and the treatment comes with a regulatory warning about its potential to cause anaphylaxis.

But the Nestlé investment underscores the bull theory. After all, about 1.2 million children have peanut allergies. That’s about 2% of the entire non-adult population of the United States. Evaluate Pharma projects that Palforzia could be a blockbuster drug that brings in more than $1 billion in annual sales by 2024.

The bet here is that, despite the challenges of administering the drug, enough parents and doctors will want to give the product a try and sales will soar.

Read on for the day’s news.

Sy Mukherjee


Verily plots a digital eye care venture with a Japanese pharma. Google parent Alphabet's life sciences arm has teamed up with Santen Pharma in order to develop a high-tech contact lens which can actually measure glucose levels. Why would you want to do something like that? The hope is to use such technology to better diagnose and treat conditions such as dry eye and glaucoma. But don't get your hopes up too much—a different iteration of this project with Alcon was shelved a few years ago. (FierceBiotech)


Gates Foundation pledges up to $100 million in coronavirus fight. The Bill & Melinda Gates Foundation is pledging up to $100 million (adding $90 million to their January pledge of $10 million) in order to diagnose, contain, and treat the Wuhan coronavirus. “Our hope is that these resources will help catalyze a rapid and effective international response. This response should be guided by science, not fear, and it should build on the steps that the World Health Organization has taken to date," said Gates Foundation CEO Mark Suzman in a statement. (Fortune)


U.S. government proposes higher Medicare payments next year. It's still in the works, but the U.S. government is proposing a modest increase to private health insurers in the Medicare Advantage program, a hike of about 0.93%. That may sound like a small number but considering the sheer volume of patients covered under the program, companies like UnitedHealth, Humana, Centene, and others appear poised for a significant boost. (Reuters)


How the menopause taboo hurts working womenby Kristen Bellstrom

Bitcoin is too slow. Can lightning labs fix that?by Jeff John Roberts

How much is an Oscar worth?by Paula Bernstein

Sign up for other Fortune newsletters.

Read More

CEO DailyCFO DailyBroadsheetData SheetTerm Sheet